|
Jan 8
|
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023
|
|
Jan 5
|
Paragon 28 Advances Foot and Ankle Specific Soft Tissue Portfolio with Launch of Grappler® Knotless Anchor System and Innovative Bridgeline™ Tape
|
|
Dec 19
|
Paragon 28 to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Nov 9
|
Market Participants Recognise Paragon 28, Inc.'s (NYSE:FNA) Revenues
|
|
Nov 8
|
Q3 2023 Paragon 28 Inc Earnings Call
|
|
Nov 7
|
Paragon 28 Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
|
|
Nov 7
|
Paragon 28 Announces New $150 Million Credit Facility Replacing Existing $90 Million Credit Facility
|
|
Nov 6
|
Paragon 28, Inc. (FNA) Surges 12.1%: Is This an Indication of Further Gains?
|
|
Sep 11
|
Paragon 28®, Inc. Receives FDA Approval for IDE Feasibility Study of Its SMART Total Talus™ System for use in Conjunction with the APEX 3D™ Total Ankle Replacement System
|